FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3204861834> ?p ?o ?g. }

• W3204861834 endingPage "436" @default.
• W3204861834 startingPage "426" @default.
• W3204861834 abstract "Purpose BRCA1/2 pathogenic variant (PV) mutations confer radiation sensitivity preclinically, but there are limited data regarding breast cancer outcomes after radiation therapy (RT) among patients with documented BRCA1/2 PV mutations versus no PV mutations. Methods and Materials This retrospective cohort study included women with clinical stage I-III breast cancer who received definitive surgery and RT and underwent BRCA1/2 genetic evaluation at the The University of Texas MD Anderson Cancer Center. Rates of locoregional recurrence (LRR), disease-specific death (DSD), toxicities, and second cancers were compared by BRCA1/2 PV status. Results Of the 2213 women who underwent BRCA1/2 testing, 63% self-reported their race as White, 13.6% as Black/African American, 17.6% as Hispanic, and 5.8% as Asian/American Indian/Alaska Native; 124 had BRCA1 and 100 had BRCA2 mutations; and 1394 (63%) received regional nodal RT. The median follow-up time for all patients was 7.4 years (95% confidence interval [CI], 7.1-7.7 years). No differences were found between the groups with and without BRCA1/2 PV mutations in 10-year cumulative incidences of LRR (with mutations: 11.6% [95% CI, 7.0%-17.6%]; without mutations: 6.6% [95% CI, 5.3%-8.0%]; P = .466) and DSD (with mutations: 12.3% [95% CI, 8.0%-17.7%]; without mutations: 13.8% [95% CI, 12.0%-15.8%]; P = .716). On multivariable analysis, BRCA1/2 status was not associated with LRR or DSD, but Black/African American patients (P = .036) and Asians/American Indians/Alaska Native patients (P = .002) were at higher risk of LRR compared with White patients, and Black/African American patients were at higher risk of DSD versus White patients (P = .004). No in-field, nonbreast second cancers were observed in the BRCA1/2 PV group. Rates of acute and late grade ≥3 radiation-related toxicity in the BCRA1/2 PV group were 5.4% (n = 12) and 0.4% (n = 1), respectively. Conclusions Oncologic outcomes in a diverse cohort of patients with breast cancer who had a germline BRCA1/2 PV mutation and were treated with RT were similar to those of patients with no mutation, supporting the use of RT according to standard indications in patients with a germline BRCA1/2 PV mutation. BRCA1/2 pathogenic variant (PV) mutations confer radiation sensitivity preclinically, but there are limited data regarding breast cancer outcomes after radiation therapy (RT) among patients with documented BRCA1/2 PV mutations versus no PV mutations. This retrospective cohort study included women with clinical stage I-III breast cancer who received definitive surgery and RT and underwent BRCA1/2 genetic evaluation at the The University of Texas MD Anderson Cancer Center. Rates of locoregional recurrence (LRR), disease-specific death (DSD), toxicities, and second cancers were compared by BRCA1/2 PV status. Of the 2213 women who underwent BRCA1/2 testing, 63% self-reported their race as White, 13.6% as Black/African American, 17.6% as Hispanic, and 5.8% as Asian/American Indian/Alaska Native; 124 had BRCA1 and 100 had BRCA2 mutations; and 1394 (63%) received regional nodal RT. The median follow-up time for all patients was 7.4 years (95% confidence interval [CI], 7.1-7.7 years). No differences were found between the groups with and without BRCA1/2 PV mutations in 10-year cumulative incidences of LRR (with mutations: 11.6% [95% CI, 7.0%-17.6%]; without mutations: 6.6% [95% CI, 5.3%-8.0%]; P = .466) and DSD (with mutations: 12.3% [95% CI, 8.0%-17.7%]; without mutations: 13.8% [95% CI, 12.0%-15.8%]; P = .716). On multivariable analysis, BRCA1/2 status was not associated with LRR or DSD, but Black/African American patients (P = .036) and Asians/American Indians/Alaska Native patients (P = .002) were at higher risk of LRR compared with White patients, and Black/African American patients were at higher risk of DSD versus White patients (P = .004). No in-field, nonbreast second cancers were observed in the BRCA1/2 PV group. Rates of acute and late grade ≥3 radiation-related toxicity in the BCRA1/2 PV group were 5.4% (n = 12) and 0.4% (n = 1), respectively. Oncologic outcomes in a diverse cohort of patients with breast cancer who had a germline BRCA1/2 PV mutation and were treated with RT were similar to those of patients with no mutation, supporting the use of RT according to standard indications in patients with a germline BRCA1/2 PV mutation." @default.
• W3204861834 created "2021-10-11" @default.
• W3204861834 creator A5003863043 @default.
• W3204861834 creator A5009965176 @default.
• W3204861834 creator A5014176442 @default.
• W3204861834 creator A5014713051 @default.
• W3204861834 creator A5015127974 @default.
• W3204861834 creator A5016731809 @default.
• W3204861834 creator A5018123323 @default.
• W3204861834 creator A5020684408 @default.
• W3204861834 creator A5024466689 @default.
• W3204861834 creator A5041542657 @default.
• W3204861834 creator A5041793550 @default.
• W3204861834 creator A5049844114 @default.
• W3204861834 creator A5071690283 @default.
• W3204861834 creator A5075931431 @default.
• W3204861834 creator A5078458765 @default.
• W3204861834 creator A5083094612 @default.
• W3204861834 creator A5084699825 @default.
• W3204861834 creator A5085458148 @default.
• W3204861834 creator A5089277393 @default.
• W3204861834 date "2022-02-01" @default.
• W3204861834 modified "2023-10-18" @default.
• W3204861834 title "Outcomes After Breast Radiation Therapy in a Diverse Patient Cohort With a Germline BRCA1/2 Mutation" @default.
• W3204861834 cites W1755658704 @default.
• W3204861834 cites W1770259999 @default.
• W3204861834 cites W1828494712 @default.
• W3204861834 cites W1945350395 @default.
• W3204861834 cites W1963572715 @default.
• W3204861834 cites W1984431444 @default.
• W3204861834 cites W1992084910 @default.
• W3204861834 cites W1993142459 @default.
• W3204861834 cites W2001171446 @default.
• W3204861834 cites W2013945615 @default.
• W3204861834 cites W2024694676 @default.
• W3204861834 cites W2032120213 @default.
• W3204861834 cites W2035720645 @default.
• W3204861834 cites W2038981426 @default.
• W3204861834 cites W2040593396 @default.
• W3204861834 cites W2041248556 @default.
• W3204861834 cites W2051409228 @default.
• W3204861834 cites W2072876845 @default.
• W3204861834 cites W2073140442 @default.
• W3204861834 cites W2076514228 @default.
• W3204861834 cites W2081943419 @default.
• W3204861834 cites W2091350790 @default.
• W3204861834 cites W2108565008 @default.
• W3204861834 cites W2124189233 @default.
• W3204861834 cites W2151836927 @default.
• W3204861834 cites W2168879581 @default.
• W3204861834 cites W2330837897 @default.
• W3204861834 cites W2589066458 @default.
• W3204861834 cites W2621592249 @default.
• W3204861834 cites W2735713677 @default.
• W3204861834 cites W2764292139 @default.
• W3204861834 cites W2900768187 @default.
• W3204861834 cites W2922868559 @default.
• W3204861834 cites W2963845618 @default.
• W3204861834 cites W2965872538 @default.
• W3204861834 cites W2967916763 @default.
• W3204861834 cites W2969864773 @default.
• W3204861834 cites W3004572568 @default.
• W3204861834 cites W3008629622 @default.
• W3204861834 cites W3014383023 @default.
• W3204861834 cites W3109120576 @default.
• W3204861834 cites W3118983547 @default.
• W3204861834 cites W3128456160 @default.
• W3204861834 cites W3165576985 @default.
• W3204861834 cites W993406450 @default.
• W3204861834 doi "https://doi.org/10.1016/j.ijrobp.2021.09.033" @default.
• W3204861834 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34610390" @default.
• W3204861834 hasPublicationYear "2022" @default.
• W3204861834 type Work @default.
• W3204861834 sameAs 3204861834 @default.
• W3204861834 citedByCount "1" @default.
• W3204861834 countsByYear W32048618342022 @default.
• W3204861834 crossrefType "journal-article" @default.
• W3204861834 hasAuthorship W3204861834A5003863043 @default.
• W3204861834 hasAuthorship W3204861834A5009965176 @default.
• W3204861834 hasAuthorship W3204861834A5014176442 @default.
• W3204861834 hasAuthorship W3204861834A5014713051 @default.
• W3204861834 hasAuthorship W3204861834A5015127974 @default.
• W3204861834 hasAuthorship W3204861834A5016731809 @default.
• W3204861834 hasAuthorship W3204861834A5018123323 @default.
• W3204861834 hasAuthorship W3204861834A5020684408 @default.
• W3204861834 hasAuthorship W3204861834A5024466689 @default.
• W3204861834 hasAuthorship W3204861834A5041542657 @default.
• W3204861834 hasAuthorship W3204861834A5041793550 @default.
• W3204861834 hasAuthorship W3204861834A5049844114 @default.
• W3204861834 hasAuthorship W3204861834A5071690283 @default.
• W3204861834 hasAuthorship W3204861834A5075931431 @default.
• W3204861834 hasAuthorship W3204861834A5078458765 @default.
• W3204861834 hasAuthorship W3204861834A5083094612 @default.
• W3204861834 hasAuthorship W3204861834A5084699825 @default.
• W3204861834 hasAuthorship W3204861834A5085458148 @default.
• W3204861834 hasAuthorship W3204861834A5089277393 @default.
• W3204861834 hasBestOaLocation W32048618342 @default.
• W3204861834 hasConcept C104317684 @default.

• next